Ads
related to: winrevair fda approval date for evenity 1 day 10 mg tablet
Search results
Results From The WOW.Com Content Network
Sotatercept, sold under the brand name Winrevair is a medication used for the treatment of pulmonary arterial hypertension. [6] It is an activin signaling inhibitor, [ 6 ] based on the extracellular domain of the activin type 2 receptor expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc). [ 9 ]
Research shows the drug increases bone formation and decreases bone resorption in postmenopausal women with low bone density. Romosozumab was approved for medical use in Japan, the United States and the European Union in 2019. [7] [10] [11] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [12]
For premium support please call: 800-290-4726 more ways to reach us
In March 2024, the FDA approved Winrevair (sotatercept-csrk), for injection, 45mg, 60mg for adults with PAH to increase exercise capacity, improve WHO functional class, and reduce the risk of ...
For premium support please call: 800-290-4726 more ways to reach us
The drug was granted priority review designation by the FDA before being approved in the US on 6 September 2019, to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). [38] [39] It is the first FDA-approved treatment for this rare lung condition. [38]
Ads
related to: winrevair fda approval date for evenity 1 day 10 mg tablet